Literature DB >> 33564471

The Effect of Inferior Rectus Muscle Thickening on Intraocular Pressure in Thyroid-Associated Ophthalmopathy.

Xiuhong Li1, Xu Bai1, Zhibin Liu1, Ming Cheng1, Jia Li1, Nian Tan1, Hongfeng Yuan1.   

Abstract

OBJECTIVE: We aimed to evaluate the effect of inferior rectus muscle thickening on intraocular pressure (IOP) in patients with thyroid-associated ophthalmopathy (TAO).
MATERIALS AND METHODS: We analyzed 33 patients with TAO (50 eyes) who presented with hypotropia in the primary position. There was significant eyeball movement restriction and inferior rectus muscle thickening was confirmed on computed tomography or magnetic resonance imaging. We measured IOP changes in patients with TAO and normal participants in the primary position and upgaze using Icare tonometer. Moreover, we measured the preoperative and postoperative IOP in 13 patients with hypotropia who underwent inferior rectus recession.
RESULTS: The average inferior rectus thickness in the TAO and control groups was 0.71 ± 0.13 mm and 0.36 ± 0.12 mm, respectively. In the TAO group, the mean IOP was 16.8 ± 2.1 mm Hg in primary position (hypotropia), which increased by 8.9 ± 2.7 mm Hg to 25.7 ± 3.1 mm Hg in upgaze (horizontal vision). In the control group, the mean IOP in the primary position (horizontal vision) was 15.1 ± 1.9 mm Hg, which increased by 2.5 ± 1.4 mm Hg to 17.6 ± 2.1 mm Hg in upgaze. Compared with normal participants, patients with TAO who presented inferior rectus muscle thickening had a significantly greater increase in the IOP (P < 0.0001). In the patients with TAO who underwent inferior rectus muscle recession, there was a postoperative reduction in the IOP in the horizontal vision by 9.4 ± 5.2 mm Hg.
CONCLUSION: Inferior rectus muscle thickening in patients with TAO causes a significant increase in the IOP upon upgaze compared to that in normal individuals. Given the ease of misdiagnosis as glaucoma, IOP measurement in patients with TAO should be performed in the primary position.
Copyright © 2021 Xiuhong Li et al.

Entities:  

Year:  2021        PMID: 33564471      PMCID: PMC7867446          DOI: 10.1155/2021/9736247

Source DB:  PubMed          Journal:  J Ophthalmol        ISSN: 2090-004X            Impact factor:   1.909


  19 in total

1.  [Behavior of ocular tension in various types of exophthalmos].

Authors:  V VANNI; R VOZZA
Journal:  Boll Ocul       Date:  1960-03

2.  Malignant exophthalmos.

Authors:  A E BRALEY
Journal:  Am J Ophthalmol       Date:  1953-09       Impact factor: 5.258

3.  Intraocular pressure in endocrinological patients with exophthalmos.

Authors:  R S Manor; O Kurz; Z Lewitus
Journal:  Ophthalmologica       Date:  1974       Impact factor: 3.250

4.  Intraocular pressure changes in normal subjects and the adhesive muscle syndrome.

Authors:  R J Zappia; J Z Winkelman; A J Gay
Journal:  Am J Ophthalmol       Date:  1971-04       Impact factor: 5.258

5.  The oculorotary muscles in Graves' disease.

Authors:  J A Dyer
Journal:  Trans Am Ophthalmol Soc       Date:  1976

Review 6.  Restrictive factors in strabismus.

Authors:  H S Metz
Journal:  Surv Ophthalmol       Date:  1983 Sep-Oct       Impact factor: 6.048

7.  Differential intraocular pressure in strabismus diagnosis.

Authors:  R A Saunders; E M Helveston; F D Ellis
Journal:  Ophthalmology       Date:  1981-01       Impact factor: 12.079

8.  Prevalence and management of elevated intraocular pressure in patients with Graves' orbitopathy.

Authors:  R Kalmann; M P Mourits
Journal:  Br J Ophthalmol       Date:  1998-07       Impact factor: 4.638

Review 9.  Intraocular pressure change in orbital disease.

Authors:  Mohamed A Nassr; Carrie L Morris; Peter A Netland; Zeynel A Karcioglu
Journal:  Surv Ophthalmol       Date:  2009 Sep-Oct       Impact factor: 6.048

10.  Upgaze intraocular pressure changes and strabismus in Graves' ophthalmopathy.

Authors:  D R Fishman; S C Benes
Journal:  J Clin Neuroophthalmol       Date:  1991-09
View more
  1 in total

1.  Glucocorticoid therapy reduces ocular hypertension in active moderate-severe thyroid-associated orbitopathy.

Authors:  Chengyang Tang; Liang Liang; Xiaoya Zheng; Hong Hu; Chun Liu; Jian Long
Journal:  BMC Endocr Disord       Date:  2022-09-23       Impact factor: 3.263

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.